Global PI3 Antibody 麻豆原创 Growth 2025-2031

Publication ID:

LPI06251109

Publication Date:

June 27, 2025

Pages:

148

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global PI3 Antibody market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
PI 3-kinase p85伪 Antibody (B-9) is an IgG1 魏 mouse monoclonal PI 3-kinase p85 alpha antibody (also designated PI3K antibody, p85 alpha antibody, PIK3R1 antibody or phosphoinositide-3-kinase regulatory subunit 1 antibody) that detects the PI 3-kinase p85 alpha protein of mouse, rat and human origin by WB, IP, IF and IHC
United States market for PI3 Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for PI3 Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for PI3 Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key PI3 Antibody players cover Merck, Thermo Fisher Scientific, Proteintech, Cell Signaling Technology, Abcam, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
The 鈥淧I3 Antibody Industry Forecast鈥� looks at past sales and reviews total world PI3 Antibody sales in 2024, providing a comprehensive analysis by region and market sector of projected PI3 Antibody sales for 2025 through 2031. With PI3 Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PI3 Antibody industry.
This Insight Report provides a comprehensive analysis of the global PI3 Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PI3 Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global PI3 Antibody market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PI3 Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PI3 Antibody.
This report presents a comprehensive overview, market shares, and growth opportunities of PI3 Antibody market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Monoclonal
Polyclonal
Segmentation by Application:
Immunochemistry (IHC)
Immunofluorescence (IF)
Immunoprecipitation (IP)
Western Blot (WB)
ELISA
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Merck
Thermo Fisher Scientific
Proteintech
Cell Signaling Technology
Abcam
ProSci Incorporated
Boster Bio
Bio-Rad
Novus Biologicals
Bioss
Abcepta
NSJBio
GeneTex
Aviva Systems Biology
LifeSpan BioSciences
Santa Cruz Biotechnology
Jingjie PTM BioLab
BioDee
Biotend
NeoBioscience Technology
Yeasen Biotechnology
Key Questions Addressed in this Report
What is the 10-year outlook for the global PI3 Antibody market?
What factors are driving PI3 Antibody market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do PI3 Antibody market opportunities vary by end market size?
How does PI3 Antibody break out by Type, by Application?

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global PI3 Antibody Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for PI3 Antibody by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for PI3 Antibody by Country/Region, 2020, 2024 & 2031
2.2 PI3 Antibody Segment by Type
2.2.1 Monoclonal
2.2.2 Polyclonal
2.3 PI3 Antibody Sales by Type
2.3.1 Global PI3 Antibody Sales 麻豆原创 Share by Type (2020-2025)
2.3.2 Global PI3 Antibody Revenue and 麻豆原创 Share by Type (2020-2025)
2.3.3 Global PI3 Antibody Sale Price by Type (2020-2025)
2.4 PI3 Antibody Segment by Application
2.4.1 Immunochemistry (IHC)
2.4.2 Immunofluorescence (IF)
2.4.3 Immunoprecipitation (IP)
2.4.4 Western Blot (WB)
2.4.5 ELISA
2.4.6 Others
2.5 PI3 Antibody Sales by Application
2.5.1 Global PI3 Antibody Sale 麻豆原创 Share by Application (2020-2025)
2.5.2 Global PI3 Antibody Revenue and 麻豆原创 Share by Application (2020-2025)
2.5.3 Global PI3 Antibody Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global PI3 Antibody Breakdown Data by Company
3.1.1 Global PI3 Antibody Annual Sales by Company (2020-2025)
3.1.2 Global PI3 Antibody Sales 麻豆原创 Share by Company (2020-2025)
3.2 Global PI3 Antibody Annual Revenue by Company (2020-2025)
3.2.1 Global PI3 Antibody Revenue by Company (2020-2025)
3.2.2 Global PI3 Antibody Revenue 麻豆原创 Share by Company (2020-2025)
3.3 Global PI3 Antibody Sale Price by Company
3.4 Key Manufacturers PI3 Antibody Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers PI3 Antibody Product Location Distribution
3.4.2 Players PI3 Antibody Products Offered
3.5 麻豆原创 Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 麻豆原创 M&A Activity & Strategy
4 World Historic Review for PI3 Antibody by Geographic Region
4.1 World Historic PI3 Antibody 麻豆原创 Size by Geographic Region (2020-2025)
4.1.1 Global PI3 Antibody Annual Sales by Geographic Region (2020-2025)
4.1.2 Global PI3 Antibody Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic PI3 Antibody 麻豆原创 Size by Country/Region (2020-2025)
4.2.1 Global PI3 Antibody Annual Sales by Country/Region (2020-2025)
4.2.2 Global PI3 Antibody Annual Revenue by Country/Region (2020-2025)
4.3 Americas PI3 Antibody Sales Growth
4.4 APAC PI3 Antibody Sales Growth
4.5 Europe PI3 Antibody Sales Growth
4.6 Middle East & Africa PI3 Antibody Sales Growth
5 Americas
5.1 Americas PI3 Antibody Sales by Country
5.1.1 Americas PI3 Antibody Sales by Country (2020-2025)
5.1.2 Americas PI3 Antibody Revenue by Country (2020-2025)
5.2 Americas PI3 Antibody Sales by Type (2020-2025)
5.3 Americas PI3 Antibody Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC PI3 Antibody Sales by Region
6.1.1 APAC PI3 Antibody Sales by Region (2020-2025)
6.1.2 APAC PI3 Antibody Revenue by Region (2020-2025)
6.2 APAC PI3 Antibody Sales by Type (2020-2025)
6.3 APAC PI3 Antibody Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe PI3 Antibody by Country
7.1.1 Europe PI3 Antibody Sales by Country (2020-2025)
7.1.2 Europe PI3 Antibody Revenue by Country (2020-2025)
7.2 Europe PI3 Antibody Sales by Type (2020-2025)
7.3 Europe PI3 Antibody Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa PI3 Antibody by Country
8.1.1 Middle East & Africa PI3 Antibody Sales by Country (2020-2025)
8.1.2 Middle East & Africa PI3 Antibody Revenue by Country (2020-2025)
8.2 Middle East & Africa PI3 Antibody Sales by Type (2020-2025)
8.3 Middle East & Africa PI3 Antibody Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of PI3 Antibody
10.3 Manufacturing Process Analysis of PI3 Antibody
10.4 Industry Chain Structure of PI3 Antibody
11 麻豆原创ing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 PI3 Antibody Distributors
11.3 PI3 Antibody Customer
12 World Forecast Review for PI3 Antibody by Geographic Region
12.1 Global PI3 Antibody 麻豆原创 Size Forecast by Region
12.1.1 Global PI3 Antibody Forecast by Region (2026-2031)
12.1.2 Global PI3 Antibody Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global PI3 Antibody Forecast by Type (2026-2031)
12.7 Global PI3 Antibody Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck PI3 Antibody Product Portfolios and Specifications
13.1.3 Merck PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 Thermo Fisher Scientific
13.2.1 Thermo Fisher Scientific Company Information
13.2.2 Thermo Fisher Scientific PI3 Antibody Product Portfolios and Specifications
13.2.3 Thermo Fisher Scientific PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Thermo Fisher Scientific Main Business Overview
13.2.5 Thermo Fisher Scientific Latest Developments
13.3 Proteintech
13.3.1 Proteintech Company Information
13.3.2 Proteintech PI3 Antibody Product Portfolios and Specifications
13.3.3 Proteintech PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Proteintech Main Business Overview
13.3.5 Proteintech Latest Developments
13.4 Cell Signaling Technology
13.4.1 Cell Signaling Technology Company Information
13.4.2 Cell Signaling Technology PI3 Antibody Product Portfolios and Specifications
13.4.3 Cell Signaling Technology PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Cell Signaling Technology Main Business Overview
13.4.5 Cell Signaling Technology Latest Developments
13.5 Abcam
13.5.1 Abcam Company Information
13.5.2 Abcam PI3 Antibody Product Portfolios and Specifications
13.5.3 Abcam PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Abcam Main Business Overview
13.5.5 Abcam Latest Developments
13.6 ProSci Incorporated
13.6.1 ProSci Incorporated Company Information
13.6.2 ProSci Incorporated PI3 Antibody Product Portfolios and Specifications
13.6.3 ProSci Incorporated PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 ProSci Incorporated Main Business Overview
13.6.5 ProSci Incorporated Latest Developments
13.7 Boster Bio
13.7.1 Boster Bio Company Information
13.7.2 Boster Bio PI3 Antibody Product Portfolios and Specifications
13.7.3 Boster Bio PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Boster Bio Main Business Overview
13.7.5 Boster Bio Latest Developments
13.8 Bio-Rad
13.8.1 Bio-Rad Company Information
13.8.2 Bio-Rad PI3 Antibody Product Portfolios and Specifications
13.8.3 Bio-Rad PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Bio-Rad Main Business Overview
13.8.5 Bio-Rad Latest Developments
13.9 Novus Biologicals
13.9.1 Novus Biologicals Company Information
13.9.2 Novus Biologicals PI3 Antibody Product Portfolios and Specifications
13.9.3 Novus Biologicals PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Novus Biologicals Main Business Overview
13.9.5 Novus Biologicals Latest Developments
13.10 Bioss
13.10.1 Bioss Company Information
13.10.2 Bioss PI3 Antibody Product Portfolios and Specifications
13.10.3 Bioss PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Bioss Main Business Overview
13.10.5 Bioss Latest Developments
13.11 Abcepta
13.11.1 Abcepta Company Information
13.11.2 Abcepta PI3 Antibody Product Portfolios and Specifications
13.11.3 Abcepta PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Abcepta Main Business Overview
13.11.5 Abcepta Latest Developments
13.12 NSJBio
13.12.1 NSJBio Company Information
13.12.2 NSJBio PI3 Antibody Product Portfolios and Specifications
13.12.3 NSJBio PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 NSJBio Main Business Overview
13.12.5 NSJBio Latest Developments
13.13 GeneTex
13.13.1 GeneTex Company Information
13.13.2 GeneTex PI3 Antibody Product Portfolios and Specifications
13.13.3 GeneTex PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 GeneTex Main Business Overview
13.13.5 GeneTex Latest Developments
13.14 Aviva Systems Biology
13.14.1 Aviva Systems Biology Company Information
13.14.2 Aviva Systems Biology PI3 Antibody Product Portfolios and Specifications
13.14.3 Aviva Systems Biology PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Aviva Systems Biology Main Business Overview
13.14.5 Aviva Systems Biology Latest Developments
13.15 LifeSpan BioSciences
13.15.1 LifeSpan BioSciences Company Information
13.15.2 LifeSpan BioSciences PI3 Antibody Product Portfolios and Specifications
13.15.3 LifeSpan BioSciences PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 LifeSpan BioSciences Main Business Overview
13.15.5 LifeSpan BioSciences Latest Developments
13.16 Santa Cruz Biotechnology
13.16.1 Santa Cruz Biotechnology Company Information
13.16.2 Santa Cruz Biotechnology PI3 Antibody Product Portfolios and Specifications
13.16.3 Santa Cruz Biotechnology PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Santa Cruz Biotechnology Main Business Overview
13.16.5 Santa Cruz Biotechnology Latest Developments
13.17 Jingjie PTM BioLab
13.17.1 Jingjie PTM BioLab Company Information
13.17.2 Jingjie PTM BioLab PI3 Antibody Product Portfolios and Specifications
13.17.3 Jingjie PTM BioLab PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Jingjie PTM BioLab Main Business Overview
13.17.5 Jingjie PTM BioLab Latest Developments
13.18 BioDee
13.18.1 BioDee Company Information
13.18.2 BioDee PI3 Antibody Product Portfolios and Specifications
13.18.3 BioDee PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.18.4 BioDee Main Business Overview
13.18.5 BioDee Latest Developments
13.19 Biotend
13.19.1 Biotend Company Information
13.19.2 Biotend PI3 Antibody Product Portfolios and Specifications
13.19.3 Biotend PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.19.4 Biotend Main Business Overview
13.19.5 Biotend Latest Developments
13.20 NeoBioscience Technology
13.20.1 NeoBioscience Technology Company Information
13.20.2 NeoBioscience Technology PI3 Antibody Product Portfolios and Specifications
13.20.3 NeoBioscience Technology PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.20.4 NeoBioscience Technology Main Business Overview
13.20.5 NeoBioscience Technology Latest Developments
13.21 Yeasen Biotechnology
13.21.1 Yeasen Biotechnology Company Information
13.21.2 Yeasen Biotechnology PI3 Antibody Product Portfolios and Specifications
13.21.3 Yeasen Biotechnology PI3 Antibody Sales, Revenue, Price and Gross Margin (2020-2025)
13.21.4 Yeasen Biotechnology Main Business Overview
13.21.5 Yeasen Biotechnology Latest Developments
14 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.